1. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
- Author
-
Williams LM, Rush AJ, Koslow SH, Wisniewski SR, Cooper NJ, Nemeroff CB, Schatzberg AF, and Gordon E
- Subjects
- Adolescent, Adult, Aged, Antidepressive Agents, Second-Generation adverse effects, Australia, Citalopram adverse effects, Cognition drug effects, Cyclohexanols adverse effects, Decision Support Techniques, Depressive Disorder, Major diagnosis, Depressive Disorder, Major psychology, Electroencephalography, Emotions drug effects, Europe, Female, Humans, Male, Middle Aged, Neuropsychological Tests, New Zealand, Prospective Studies, Psychiatric Status Rating Scales, Quality of Life, Selective Serotonin Reuptake Inhibitors adverse effects, Sertraline adverse effects, Social Behavior, Time Factors, Treatment Outcome, United States, Venlafaxine Hydrochloride, Young Adult, Antidepressive Agents, Second-Generation therapeutic use, Citalopram therapeutic use, Cyclohexanols therapeutic use, Depressive Disorder, Major drug therapy, Research Design, Selective Serotonin Reuptake Inhibitors therapeutic use, Sertraline therapeutic use
- Abstract
Background: Clinically useful treatment moderators of Major Depressive Disorder (MDD) have not yet been identified, though some baseline predictors of treatment outcome have been proposed. The aim of iSPOT-D is to identify pretreatment measures that predict or moderate MDD treatment response or remission to escitalopram, sertraline or venlafaxine; and develop a model that incorporates multiple predictors and moderators., Methods/design: The International Study to Predict Optimized Treatment - in Depression (iSPOT-D) is a multi-centre, international, randomized, prospective, open-label trial. It is enrolling 2016 MDD outpatients (ages 18-65) from primary or specialty care practices (672 per treatment arm; 672 age-, sex- and education-matched healthy controls). Study-eligible patients are antidepressant medication (ADM) naïve or willing to undergo a one-week wash-out of any non-protocol ADM, and cannot have had an inadequate response to protocol ADM. Baseline assessments include symptoms; distress; daily function; cognitive performance; electroencephalogram and event-related potentials; heart rate and genetic measures. A subset of these baseline assessments are repeated after eight weeks of treatment. Outcomes include the 17-item Hamilton Rating Scale for Depression (primary) and self-reported depressive symptoms, social functioning, quality of life, emotional regulation, and side-effect burden (secondary). Participants may then enter a naturalistic telephone follow-up at weeks 12, 16, 24 and 52. The first half of the sample will be used to identify potential predictors and moderators, and the second half to replicate and confirm., Discussion: First enrolment was in December 2008, and is ongoing. iSPOT-D evaluates clinical and biological predictors of treatment response in the largest known sample of MDD collected worldwide., Trial Registration: International Study to Predict Optimised Treatment - in Depression (iSPOT-D) ClinicalTrials.gov Identifier: NCT00693849. URL: http://clinicaltrials.gov/ct2/show/NCT00693849?term=International+Study+to+Predict+Optimized+Treatment+for+Depression&rank=1
- Published
- 2011
- Full Text
- View/download PDF